Results 61 to 70 of about 79,532,914 (276)
Benign prostatic hyperplasia (BPH) is a disease that affects over 50% of males aged 50 years or older. In men aged >80 years, the incidence is 90%. BPH occurs in 9-25% of males aged 40 to 79 years. Fifty percent of patients with BPH are symptomatic.
Norma Marigliano, Domenico Galasso
doaj +1 more source
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green +15 more
wiley +1 more source
Purpose: The current study is aimed to assess whether a longer duration of 5α-reductase inhibitor (5α-RI) exposure was asso-ciated with higher rate of permanent erectile dysfunction (ED) in a rat model.
Hyun Hwan Sung +6 more
doaj +1 more source
Underground Signals: The Ecological Power of Root Volatiles
Root volatiles mediate rhizosphere chemical communication, shaping interactions among plants, microbes, herbivores, and natural enemies. Their production, transport, and perception underpin ecological adaptation, multitrophic interactions, and plant resilience, offering opportunities for sustainable crop protection, resilient agroecosystems, and ...
Xueyao Cao +31 more
wiley +1 more source
Effects of 5-alpha reductase inhibitors
The use of 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) and other diseases has been proposed and studied. However, the controversy about its benefits and harms for other diseases has persisted. In this review, we will discuss the newly identified effects of 5ARIs based on recently published studies.These ...
Joo Yong, Lee, Kang Su, Cho
openaire +3 more sources
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
The benefits of dual inhibition of 5 alpha reductase
In humans, androgens balance cell proliferation and apoptosis, ensuring normal growth and development of the prostate, but also driving pathologic gland enlargement in benign prostatic hyperplasia (BPH) and prostate cancer.
B. Djavan, MIRONE, VINCENZO
core +1 more source
A nanomodulator called L‐Arginine/lificiguat@Copper‐hollow Prussian blue@Calcium phosphate nanoparticles is constructed to launch a self‐amplifying “avalanche effect” in tumor cells. The ensuing cascade, triggered by the acidic tumor microenvironment and near‐infrared light, induces calcium overload, generates a reactive oxygen species and reactive ...
Hongmei Zhou +9 more
wiley +1 more source
Update on the use of dutasteride in the management of benign prostatic hypertrophy
Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade ...
Joe Miller, Thomas H Tarter
doaj
Chemical Bond‐Orchestrated Energy Depletion to Augment Lung Cancer Chemo‐Immunotherapy
This study grafted dichloroacetic acid (DCA) into perylenediimide (PDI) skeleton via ionic or covalent bond to create novel metabolic agent PDIC‐AC and PDIC‐NAC, explicitly elaborated the underlying energy metabolism and therapeutic mechanism, and developed a promising strategy for energy metabolism‐targeting chemo‐immunotherapy by chemical bond ...
Xuejie Zhao +5 more
wiley +1 more source

